DiaTech Oncology, provider of the drug response-profiling test CorrectChemo®, is now available through NextGxDx’s online genetic testing marketplace, GeneSourceTM and GeneConnect™. Adding the assay to its platforms continues NextGxDx’s efforts to broaden the scope of cancer diagnostics in its GeneSource catalog with emerging cell-based assays. CorrectChemo is a diagnostic test that delivers a ranking of the ability of chemotherapeutic agents to kill tumor cells in an individual patient sample within 72 hours.
